Selective LXR agonist, DMHCA, corrects the retina-bone marrow axis in type 2 diabetes
C. P. Vieira, S. D. Fortmann, M. Hossain, A. L. Longhini, S. S. Hammer, B. Asare-Bediako, D. K. Crossman, M. S. Sielski, Y. Adu-Agyeiwaah, M. Dupont, J. L. Floyd, S. Li Calzi, T. Lydic, R. S. Welner, G. J. Blanchard, , M. B. Grant
This study shows that DMHCA, a selective LXR agonist, corrects the retina-bone marrow axis in type 2 diabetes by restoring retinal function, cholesterol homeostasis, and hematopoietic stem cell balance.
bioRxiv · Feb 11, 2020 · PreprintCell Biology